

• Name:	Yoon Ji Choi
• Current Position & Affiliation:	Korea University College of Medicine Associate Professor
• Country:	Korea

• Educational Background:

Academic Qualifications (most current date first)			
Degree	Date (YYYY)	Institution, Country	
M.D.	2006	Korea University College of Medicine, Seoul, H	Korea
M.S.	2010	Korea University College of Medicine, Seoul, H	Korea
Ph.D.	2015	Korea University College of Medicine, Seoul, H	Korea

• Professional Experience:

Current and Previous 4 Relevant Positions Including Academic Appointments			
Start and End dates	Title	Institution, Country	
Mar 2020 – Sep 2016 – Feb 2020 Mar 2016 – Aug 2016 Mar 2013 – Feb 2016 Mar 2012 – Feb 2013 Mar 2011 – Feb 2012 Mar 2007 – Feb	Associate Profess Assistant Profess Clinical Assis Professor Clinical fellowshi Clinical fellowshi Clinical fellowshi Resident	br stant korea University Anam Hospital, Seoul, Korea p korea University Anam Hospital, Seoul, Korea Asan Medical Center, Seoul, Korea	
2011		Korea	

Professional Organizations:

Korean Society of Medical Oncology

Korean Cancer Study Group (member of Lung Cancer subcommittee & GUGY subcommittee)

The Korean Cancer Association

The Korean Society for Head & Neck Oncology

www.ksmo.or.kr/ksmo2020



• Main Scientific Publications:

- The serum bone morphogenetic protein-2 level in non-small-cell lung cancer patients. <u>Choi YJ</u>, Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. *Med Oncol*. 2012 Jun;29(2):582-8.
- Werniche's encephalopathy following allogeneic hematopoietic stem cell transplantation. <u>Choi YJ</u>, Park SJ, Kim JS, Kang EJ, Choi CW, Kim BS. *Korean J Hematol.* 2010 Dec;45(4):279-81.
- 3. Small bowel carcinoma in young patient detected by double-balloon enteroscopy. <u>Choi YJ</u>, Jung SW, Um JW, Lee ES, Koo JS, Yim HJ, Lee SW, Choi JH. *Korean J Gastroenterol.* 2011 Oct 25;58(4):217-20.
- The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. Lee S-Y, <u>Choi</u> <u>YJ</u>, Chang WJ, Shin SW, Kim YH, Kim ST. *J Gastrointest Oncol* 2014;5(6):457-462.
- Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study. <u>Choi YJ</u>, Lee SH, Ahn J-H, Lee K-H, You D, Hong B, Hong JH, Ahn H. *Br J Cancer*. 2015;112:260-265.
- Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. <u>Choi YJ</u>, Lee DH, Choi CM, Lee JS, Lee SJ, Ahn J-H, Kim S-W. *BMC Cancer*. 2015;15:763.
- The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer. <u>Choi YJ</u>, Chang WJ, Shin SW, Park KH, Kim ST, Kim YJ. Oncotargets and Therapy. 2016;9:3307-3312.
- 8. A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin. Kim JS, Lim SY, Hwang J, Kang EJ, <u>Choi YJ</u>. J Korean Med Sci. 2017;32:1879-1884.
- 9. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). <u>Choi YJ</u>, Kim HS, Park SH, Kim B-S, Kim KH, Lee HJ, Song HS, Shin D-Y, Lee HY, Kim H-G, Lee KH, Lee JL, Park KH. *Cancer Res Treat*. 2018 Ict;50(4):1252-1259.
- 10. Association between hand grip strength and impaired health-related quality of life in Korean cancer survivors: a cross-sectional study. Paek J, <u>Choi YJ</u>. BMJ Open. 2019 Sep 8;9(9):e030938.